Cargando…
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis
BACKGROUND: Optimal doses of first-line drugs for treatment of drug-susceptible tuberculosis in children and young adolescents remain uncertain. We aimed to determine whether children treated using World Health Organization–recommended or higher doses of first-line drugs achieve successful outcomes...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156125/ https://www.ncbi.nlm.nih.gov/pubmed/36609692 http://dx.doi.org/10.1093/cid/ciac973 |
_version_ | 1785036474990723072 |
---|---|
author | Solans, Belén P Béranger, Agathe Radtke, Kendra Mohamed, Ali Mirzayev, Fuad Gegia, Medea Linh, Nguyen Nhat Schumacher, Samuel G Nahid, Payam Savic, Radojka M |
author_facet | Solans, Belén P Béranger, Agathe Radtke, Kendra Mohamed, Ali Mirzayev, Fuad Gegia, Medea Linh, Nguyen Nhat Schumacher, Samuel G Nahid, Payam Savic, Radojka M |
author_sort | Solans, Belén P |
collection | PubMed |
description | BACKGROUND: Optimal doses of first-line drugs for treatment of drug-susceptible tuberculosis in children and young adolescents remain uncertain. We aimed to determine whether children treated using World Health Organization–recommended or higher doses of first-line drugs achieve successful outcomes and sufficient pharmacokinetic (PK) exposures. METHODS: Titles, abstracts, and full-text articles were screened. We searched PubMed, EMBASE, CENTRAL, and trial registries from 2010 to 2021. We included studies in children aged <18 years being treated for drug-susceptible tuberculosis with rifampicin (RIF), pyrazinamide, isoniazid, and ethambutol. Outcomes were treatment success rates and drug exposures. The protocol for the systematic review was preregistered in PROSPERO (no. CRD42021274222). RESULTS: Of 304 studies identified, 46 were eligible for full-text review, and 12 and 18 articles were included for the efficacy and PK analyses, respectively. Of 1830 children included in the efficacy analysis, 82% had favorable outcomes (range, 25%–95%). At World Health Organization–recommended doses, exposures to RIF, pyrazinamide, and ethambutol were lower in children than in adults. Children ≤6 years old have 35% lower areas under the concentration-time curve (AUCs) than older children (mean of 14.4 [95% CI 9.9–18.8] vs 22.0 [13.8–30.1] μg·h/mL) and children with human immunodeficiency virus (HIV) had 35% lower RIF AUCs than HIV-negative children (17.3 [11.4–23.2] vs 26.5 [21.3–31.7] μg·h/mL). Heterogeneity and small sample sizes were major limitations. CONCLUSIONS: There is large variability in outcomes, with an average of 82% favorable outcomes. Drug exposures are lower in children than in adults. Younger children and/or those with HIV are underexposed to RIF. Standardization of PK pediatric studies and individual patient data analysis with safety assessment are needed to inform optimal dosing. |
format | Online Article Text |
id | pubmed-10156125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-101561252023-05-04 Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis Solans, Belén P Béranger, Agathe Radtke, Kendra Mohamed, Ali Mirzayev, Fuad Gegia, Medea Linh, Nguyen Nhat Schumacher, Samuel G Nahid, Payam Savic, Radojka M Clin Infect Dis Major Article BACKGROUND: Optimal doses of first-line drugs for treatment of drug-susceptible tuberculosis in children and young adolescents remain uncertain. We aimed to determine whether children treated using World Health Organization–recommended or higher doses of first-line drugs achieve successful outcomes and sufficient pharmacokinetic (PK) exposures. METHODS: Titles, abstracts, and full-text articles were screened. We searched PubMed, EMBASE, CENTRAL, and trial registries from 2010 to 2021. We included studies in children aged <18 years being treated for drug-susceptible tuberculosis with rifampicin (RIF), pyrazinamide, isoniazid, and ethambutol. Outcomes were treatment success rates and drug exposures. The protocol for the systematic review was preregistered in PROSPERO (no. CRD42021274222). RESULTS: Of 304 studies identified, 46 were eligible for full-text review, and 12 and 18 articles were included for the efficacy and PK analyses, respectively. Of 1830 children included in the efficacy analysis, 82% had favorable outcomes (range, 25%–95%). At World Health Organization–recommended doses, exposures to RIF, pyrazinamide, and ethambutol were lower in children than in adults. Children ≤6 years old have 35% lower areas under the concentration-time curve (AUCs) than older children (mean of 14.4 [95% CI 9.9–18.8] vs 22.0 [13.8–30.1] μg·h/mL) and children with human immunodeficiency virus (HIV) had 35% lower RIF AUCs than HIV-negative children (17.3 [11.4–23.2] vs 26.5 [21.3–31.7] μg·h/mL). Heterogeneity and small sample sizes were major limitations. CONCLUSIONS: There is large variability in outcomes, with an average of 82% favorable outcomes. Drug exposures are lower in children than in adults. Younger children and/or those with HIV are underexposed to RIF. Standardization of PK pediatric studies and individual patient data analysis with safety assessment are needed to inform optimal dosing. Oxford University Press 2023-01-04 /pmc/articles/PMC10156125/ /pubmed/36609692 http://dx.doi.org/10.1093/cid/ciac973 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Solans, Belén P Béranger, Agathe Radtke, Kendra Mohamed, Ali Mirzayev, Fuad Gegia, Medea Linh, Nguyen Nhat Schumacher, Samuel G Nahid, Payam Savic, Radojka M Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis |
title | Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis |
title_full | Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis |
title_fullStr | Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis |
title_short | Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis |
title_sort | effectiveness and pharmacokinetic exposures of first-line drugs used to treat drug-susceptible tuberculosis in children: a systematic review and meta-analysis |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156125/ https://www.ncbi.nlm.nih.gov/pubmed/36609692 http://dx.doi.org/10.1093/cid/ciac973 |
work_keys_str_mv | AT solansbelenp effectivenessandpharmacokineticexposuresoffirstlinedrugsusedtotreatdrugsusceptibletuberculosisinchildrenasystematicreviewandmetaanalysis AT berangeragathe effectivenessandpharmacokineticexposuresoffirstlinedrugsusedtotreatdrugsusceptibletuberculosisinchildrenasystematicreviewandmetaanalysis AT radtkekendra effectivenessandpharmacokineticexposuresoffirstlinedrugsusedtotreatdrugsusceptibletuberculosisinchildrenasystematicreviewandmetaanalysis AT mohamedali effectivenessandpharmacokineticexposuresoffirstlinedrugsusedtotreatdrugsusceptibletuberculosisinchildrenasystematicreviewandmetaanalysis AT mirzayevfuad effectivenessandpharmacokineticexposuresoffirstlinedrugsusedtotreatdrugsusceptibletuberculosisinchildrenasystematicreviewandmetaanalysis AT gegiamedea effectivenessandpharmacokineticexposuresoffirstlinedrugsusedtotreatdrugsusceptibletuberculosisinchildrenasystematicreviewandmetaanalysis AT linhnguyennhat effectivenessandpharmacokineticexposuresoffirstlinedrugsusedtotreatdrugsusceptibletuberculosisinchildrenasystematicreviewandmetaanalysis AT schumachersamuelg effectivenessandpharmacokineticexposuresoffirstlinedrugsusedtotreatdrugsusceptibletuberculosisinchildrenasystematicreviewandmetaanalysis AT nahidpayam effectivenessandpharmacokineticexposuresoffirstlinedrugsusedtotreatdrugsusceptibletuberculosisinchildrenasystematicreviewandmetaanalysis AT savicradojkam effectivenessandpharmacokineticexposuresoffirstlinedrugsusedtotreatdrugsusceptibletuberculosisinchildrenasystematicreviewandmetaanalysis |